On August 10, 2026, Novo Nordisk and AWS announced a strategic AI partnership to accelerate drug discovery and establish a co-innovation hub in London. The collaboration deploys Amazon Bio Discovery and Bedrock AgentCore to streamline workflows. This move follows recent pipeline setbacks for Novo Nordisk, including the Phase 3 failure of ziltivekimab and the discontinuation of monlunabant, amid intense market competition from Eli Lilly.
AWS strategic partnership announcement
- ▪The August 2026 AWS agreement represents Novo Nordisk's third major AI infrastructure commitment in approximately 12 months, following partnerships with the Danish Centre for AI Innovation in June 2025 and OpenAI in April 2026.
- ▪Novo Nordisk and Amazon Web Services (AWS) announced a strategic AI partnership on August 10, 2026, naming AWS as Novo Nordisk's preferred cloud provider and strategic AI partner.
- ▪The partnership between Novo Nordisk and AWS aims to combine Novo Nordisk's research in chronic diseases with AWS's cloud infrastructure and AI services to accelerate drug discovery.
- ▪Novo Nordisk's broader relationship with Amazon also includes collaborations with Amazon Pharmacy, Amazon Ads, and One Medical to improve how approved therapies are marketed and delivered.
London co-innovation hub
- ▪The London co-innovation hub is designed to reduce handoffs between computational analysis and laboratory research, compressing the timeline from drug target identification to the first human dose.
- ▪AWS Forward Deployed Engineers, backed by a $1 billion investment announced in June 2026, will physically embed within Novo Nordisk's London facility to work directly on AI projects.
- ▪Novo Nordisk and AWS established a co-innovation hub at Novo Nordisk's existing London facility to bring together AWS engineers, AI specialists, and applied scientists with Novo Nordisk's research and development teams.
Amazon Bio Discovery platform
- ▪Memorial Sloan Kettering Cancer Center previously used Amazon Bio Discovery to design and route 100,000 novel antibody candidates for synthesis testing in a matter of weeks.
- ▪Amazon Bio Discovery integrates with contract research organizations Twist Bioscience and Ginkgo Bioworks to synthesize and test high-ranked molecule candidates, routing results back to fine-tune the models.
- ▪The partnership deploys Amazon Bio Discovery, an agentic AI application launched in April 2026, which allows Novo Nordisk biologists to design drug molecules using plain-language instructions instead of code.
- ▪Amazon Bio Discovery features a catalog of over 40 biological foundation models, including an antibody dataset model developed in partnership with the Gray Lab at Johns Hopkins.
Recent pipeline setbacks
- ▪Novo Nordisk faces intensifying market pressure from Eli Lilly, which signed a $2.75 billion deal with Insilico Medicine in March 2026 to acquire AI-designed drug candidates.
- ▪In late July 2026, Novo Nordisk experienced pipeline setbacks when its cardiovascular drug ziltivekimab failed its primary endpoint in the Phase 3 ZEUS trial, and the company ended development of obesity candidate monlunabant.
Existing AWS deployments
- ▪Novo Nordisk used Anthropic's Claude 3.5 through Amazon Bedrock to reduce the time required to generate certain clinical documentation by more than 90 percent.
- ▪Prior to the August 2026 agreement, more than 25,000 Novo Nordisk employees used a generative AI platform built on Amazon Bedrock to create chatbots for over 2,500 non-regulated use cases.
AI agent infrastructure
- ▪A security vulnerability assigned as CVE-2026-18830 was identified in the Amazon Bedrock AgentCore InvokeHarness API, which AWS patched server-side on July 31, 2026.
- ▪Novo Nordisk will leverage Amazon Bedrock AgentCore, an AWS infrastructure for deploying and operating autonomous AI agents, across its research and operational workflows.
Story comments
Loading comments…